Dialkyl Tryptamine Derivatives for Controlled Hydrolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for pure, well-characterized dialkytryptamines, including specific salts, solvates, and crystalline forms thereof, to address the therapeutic potential of psilocin for treating mood disorders, anxiety, addiction, PTSD, and other psychological and neurological disorders, as well as sexual and women's health disorders, due to the lack of availability of such compounds.
Innovation Solution
Development of tryptamine derivatives of formula (I) and (Ia), including pharmaceutically acceptable salts and excipients, for use in pharmaceutical compositions to treat various disorders by administering therapeutically effective amounts of these compounds, which can modulate neurotransmitter activity and provide enhanced bioavailability through controlled hydrolysis rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin is used as the therapeutic compound, then therapeutic potential for mood disorders is addressed, but lack of availability of pure, well-characterized dialkytryptamines limits therapeutic efficacy and bioavailability
Solution Approach 1:
The patent modifies the chemical structure of psilocybin by changing the alkyl chain lengths at positions R1 and R2 to create a series of dialkytryptamine derivatives with varying properties. This structural parameter change enables optimization of bioavailability, therapeutic efficacy, and characterizability while maintaining the core therapeutic activity for mood disorders.
Solution Approach 2:
The patent systematically varies the alkyl chain segments (R1 and R2) independently to create multiple discrete compounds (Formula I and Ia). This segmentation allows each compound to be individually characterized and optimized for specific therapeutic indications, providing a library of well-defined substances rather than a single undefined mixture.
2Productivity
If psilocin is used to treat psychological disorders, then therapeutic activity is achieved, but unavailability of controlled hydrolysis rates and optimized bioavailability reduces treatment effectiveness
Solution Approach 1:
The patent introduces prodrug compounds (Formula I and Ia) that undergo controlled hydrolysis to release the active tryptamine species. This preliminary action allows the compound to be administered in a stable, non-active form that converts reliably to the active form at the target site, providing controlled and predictable therapeutic activity.
Solution Approach 2:
The patent uses the prodrug compounds as intermediaries between administration and active therapeutic effect. These compounds (Formula I and Ia) serve as mediators that convert to the active tryptamine form through controlled hydrolysis, enabling reliable and controlled delivery of the active substance with optimized bioavailability.
3Measurement precision
If pure dialkytryptamines are synthesized, then therapeutic specificity is improved, but complexity of characterization and formulation increases
Solution Approach 1:
The patent introduces specific local modifications at positions R3-R8 (including R3-R4, R5, R6-R8) to create distinct chemical environments that facilitate reliable characterization. These local structural variations provide unique physical and chemical properties for each compound, enabling precise measurement and identification while maintaining manageable formulation complexity through systematic design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tryptamine derivatives offer improved therapeutic efficacy by modulating neurotransmitter activity, treating inflammation and pain, and addressing psychological, neurological, and sexual health disorders, with enhanced bioavailability and controlled hydrolysis rates compared to psilocybin.
Implementation Method 1
controlled hydrolysis rates
Data Source
AI summary
The disclosure relates to a compound of formula (I):The disclosure also relates compound of formula (Ia):The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).